<DOC>
	<DOCNO>NCT02405442</DOCNO>
	<brief_summary>This study primarily evaluate safety efficacy GS-5745 adult active Crohn 's disease . The study consist Blinded Treatment Period 8 week follow Open Label Extension . Participants complete Blinded Treatment Period eligible enroll optional Open Label Extension additional 44 week . Participants complete Week 52 assessment eligible enter Extended Treatment Phase continue treatment GS-5745 additional 156 week .</brief_summary>
	<brief_title>Safety Efficacy GS-5745 Participants With Moderately Severely Active Crohn 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Key Ability provide write informed consent Females childbearing potential must negative pregnancy test screen baseline Documented diagnosis Crohn 's disease minimum disease duration 6 month involvement ileum and/or colon minimum Moderately severely active Crohn 's disease define CDAI total score 220450 ( inclusive ) AND evidence active disease measure ileocolonoscopy Within previous 5 year , demonstrate inadequate clinical response intolerance least one follow agent : Corticosteroids : Immunomodulators : tumor necrosis factoralpha ( TNFÎ± ) Antagonists : Vedolizumab : May receive follow drug : Oral 5aminosalicylate ( 5ASA ) Oral corticosteroid therapy Antidiarrheals chronic diarrhea Azathioprine 6mercaptopurine ( 6MP ) methotrexate Antibiotics treatment Crohn 's Disease Able comply dose instruction study drug able comply study visit requirement Key Evidence abscess screen Extensive colonic resection ( subtotal total colectomy ) history &gt; 2 small bowel resection Ileostomy , colostomy , symptomatic stenosis intestine Current use oral corticosteroid dose equivalent &gt; 30 mg/day prednisone Ulcerative colitis indeterminate colitis Short bowel syndrome Stool sample positive Clostridium difficile ( C. difficile ) toxin , E. coli , Salmonella , Shigella , Campylobacter Yersinia Treatment monoclonal antibody within 4 week screen History evidence colonic mucosal dysplasia HIV , hepatitis B , hepatitis C , tuberculosis ( TB ) infection Participated clinical study investigational drug biologic within last 30 day Any chronic medical condition ( include , limited , cardiac pulmonary disease ) , opinion investigator , would make individual unsuitable study would prevent compliance study protocol NOTE : Other protocol define Inclusion/ Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>